In an interview with MedTech Dive, Olympus CEO Bob White and Chief Strategy Officer Gabriela Kaynor discussed the company’s renewed focus on quality and innovation following a turbulent year that included an FDA import alert on some Japan-made devices. Despite setbacks, Olympus is investing heavily in AI-powered endoscopy tools and a GI-focused surgical robot through its new venture, Swan Endosurgical, formed with Revival Healthcare Capital.
The firm’s recently launched Olysense AI suite includes real-time polyp detection and characterization tools for colonoscopy. White emphasized Olympus’ intent to balance AI, robotics, and single-use scopes while maintaining reusable platforms for specific specialties. Kaynor added that endoluminal robotics could expand access to complex GI procedures, where training barriers are high.